Tarsus Pharmaceuticals, Inc. TARS Lease Liability Payments - Due Year Two
Lease Liability Payments - Due Year Two at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s lease liability payments - due year two.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s lease liability payments - due year two?
- Tarsus Pharmaceuticals, Inc. (TARS) reported lease liability payments - due year two of $2.7M in Q1 2026.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s lease liability payments - due year two?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s lease liability payments - due year two has grown at a 54.5% compound annual growth rate (CAGR), from $298K to $2.63M.
- What does lease liability payments - due year two mean?
- This metric identifies the total cash payments required for operating and finance leases in the second year following the current balance sheet date. It helps investors forecast long-term fixed cost commitments and cash flow requirements. It is essential for modeling the company's future solvency and operational leverage.